Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Invested Capital (2016 - 2025)

Amicus Therapeutics' Invested Capital history spans 16 years, with the latest figure at $666.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 14.16% year-over-year to $666.9 million, compared with a TTM value of $666.9 million through Dec 2025, up 14.16%, and an annual FY2025 reading of $666.9 million, up 14.16% over the prior year.
  • Invested Capital for Q4 2025 was $666.9 million at Amicus Therapeutics, up from $622.4 million in the prior quarter.
  • The five-year high for Invested Capital was $765.3 million in Q3 2021, with the low at $495.2 million in Q1 2023.
  • Average Invested Capital over 5 years is $583.8 million, with a median of $576.2 million recorded in 2024.
  • Year-over-year, Invested Capital surged 58.29% in 2021 and then plummeted 31.55% in 2022.
  • Tracing FOLD's Invested Capital over 5 years: stood at $696.7 million in 2021, then dropped by 26.08% to $515.0 million in 2022, then rose by 6.41% to $548.0 million in 2023, then grew by 6.59% to $584.2 million in 2024, then increased by 14.16% to $666.9 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Invested Capital are $666.9 million (Q4 2025), $622.4 million (Q3 2025), and $595.6 million (Q2 2025).